Drug
Adimanebart
Adimanebart: highest development phase Phase 3, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Adimanebart IV NCT07746089 | Phase 3 | Congenital Myasthenic Syndrome |
Latest
No recent events.
Follow Adimanebart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.